Hossein Borghaei, DO, MS

MADRID — Hossein Borghaei, DO, MS, discussed results from the ALINA study on ALK-positive non-small cell lung cancer, which were presented at ESMO Congress, in a video interview with Healio.

MADRID — Healio spoke with Hossein Borghaei, DO, MS, about the results of the MARIPOSA-2 trial, which were presented at ESMO Congress.

MADRID — In this video interview with Healio, Hossein Borghaei, DO, MS, talked about results from the MARIPOSA study presented at ESMO Congress.

MADRID — Hossein Borghaei, DO, MS, discussed results from the PAPILLON trial, which combined amivantamab and chemotherapy as first-line treatment for EGFR exon 20 insertion-mutated non-small cell lung cancer, in a video interview.

In this video, Hossein Borghaei, DO, MS, discusses safety, response and survival data of patients with small cell lung cancer who received tarlatamab, a half-life extended bispecific T-cell engager, or HLE BiTE.

At this year’s International Association for the Study of Lung Cancer World Conference on Lung Cancer, one of the more talked about presentations was IMpower010.

Hossein Borghaei, DO, MS, spoke with Healio about findings from the S1800A Lung-MAP substudy and CheckMate 816.

CHICAGO — Chemoimmunotherapy and immunotherapy alone conferred comparable benefit as first-line therapy for most patients with advanced non-small cell lung cancer and high PD-L1 expression, results presented at ASCO Annual Meeting showed.

CHICAGO — A new combination therapy benefitted certain patients with immunotherapy-resistant advanced non-small cell lung cancer, according to randomized phase 2 study results presented at ASCO Annual Meeting.

In this video, Hossein Borghaei, DO, MS, discussed the impact of the pandemic on the care of patients with lung cancer, noting that at this year’s International Lung Cancer Congress, most conversations about COVID-19 took place off the podium.